Use of OROS ® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses

Wiener Klinische Wochenschrift

Volumn 124, Issue 1-2, 2012, Pages 25-31

  Ringe, Johann D ^a   Schäfer, Susanne ^b   Wimmer, Antonie M ^c   Giesecke, Thorsten ^c  

^a KLINIKUM LEVERKUSEN   (Germany)

^b AMS Advanced Medical Services GmbH   (Germany)

^c JANSSEN CILAG GMBH   (Germany)

Author keywords

Dosing; Hydromorphone; Opioid; OROS ; Osteoarthritis; Osteoporosis

Indexed keywords

HYDROMORPHONE; OPIATE; NARCOTIC ANALGESIC AGENT;

AGE DISTRIBUTION; ARTICLE; CHRONIC PAIN; CONSTIPATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG TOLERABILITY; FATIGUE; FRAGILITY FRACTURE; HUMAN; NAUSEA; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; PATIENT SATISFACTION; POST HOC ANALYSIS; PROSPECTIVE STUDY; PRURITUS; TREATMENT DURATION; VOMITING; AGED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; GERMANY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; TREATMENT OUTCOME;

AGED; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HUMANS; HYDROMORPHONE; MALE; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84862269223     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-011-0076-y     Document Type: Article

References (30)

1. Gupta S, Hawker GA, Laporte A, Croxford R, Coyte PC. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatology (Oxford) 2005;44(12):1531-7. (Pubitemid 41742470)
2. Ethgen O, Kahler KH, Kong SX, Reginster JY, Wolfe F. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol 2002;29(6):1147-55. (Pubitemid 34601946)
3. Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 2006;33(6):1152-8. (Pubitemid 43825470)
4. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174(11):1589-94. (Pubitemid 43829515)
5. Ballantyne J, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349(20):1943-53. (Pubitemid 37409712)
6. Otis J, Rothman M. A phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic non-malignant pain. Curr Med Res Opin 2006;22(8):1493-501. (Pubitemid 44297428)
7. Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or non-malignant pain. J Pain Symptom Manage 2002;23(5):355-68. (Pubitemid 34463005)
8. Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2001;97(4):827-36.
9. Angst MS, Drover DR, Lotsch J, et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001;94(1):63-73. (Pubitemid 32055179)
10. ® formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol 2007;7:2.
11. ® formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008;24(1):297-305. (Pubitemid 351160261)
12. ® hydromorphone and SR morphine for patients with chronic cancer pain. BMC Palliative Care 2008;7:17.
13. ® hydromorphone for the management of chronic non-malignant pain: a dose-conversion and titration study. Int J Clin Pract 2007;61(10):1671-6. (Pubitemid 47404391)
14. ® hydromorphone and twicedaily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007;29(5):874-88. (Pubitemid 47223433)
15. ® hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin 2010;26(6):1505-18.
16. ® hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 2010;10(5):404-15.
17. ® hydromorphone and use of breakthrough medication in patients with chronic severe pain due to osteoporosis and osteoarthritis. Poster presented at Deutsche Gesellschaft zum Studium des Schmerzes EV. (DGSS) meeting 7-10 October 2009, Berlin, Germany.
18. ® hydromorphone in patients with chronic severe pain due to osteoporosis and arthritis in a daily routine setting. Poster presented at Deutsche Gesellschaft sum Studium des Schmerzes E V. (DGSS) meeting 7-10 October 2009, Berlin, Germany.
19. ® hydromorphone in elderly patients with chronic severe pain due to osteoporosis and osteoarthritis in a daily routine setting. Poster presented at Deutsche Gesellschaft zum Stadium des Schmerzes EV. (DGSS) meeting 7-10 October 2009, Berlin, Germany.
20. ® hydromorphone 4 mg compared to higher starting doses in patients with chronic severe pain due to chronic osteoporosis and arthritis. Poster presented at Deutsche Geselleschaft xum Studium des Schmerzes EV. (DGSS) meeting 7-10 October 2009, Berlin, Germany.
21. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised National Institute of Mental Health, Rockville, MD. 1976.
22. Patanwala AE, Jarzyna DL, Miller MD, Erstad BL. Comparison of opioid requirements and analgesic response in opioid-tolerant versus opioid-naïve patients after total knee arthroplasty. Pharmacotherapy 2008;28(12):1453-60.
23. de Leon-Casasola OA, Myers DP, Donaparthi S, et al. A comparison of postoperative epidural analgesia between patients with chronic cancer taking high doses of oral opioids versus opioid-naïve patients. Anesth Analg 1993;76(2):302-7. (Pubitemid 23085736)
24. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11(2):S105-20. (Pubitemid 351682081)
25. Gana TJ, Pascual ML, Fleming RR, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006;22(7):1391-401. (Pubitemid 44085591)
26. Koizumi W, Toma H, Watanabe K, et al. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naïve cancer pain patients, starting with 5 mg tablets. Jpn J Clin Oncol 2004;34(10):608-14. (Pubitemid 40662716)
27. ® SMAT12) in patients with chronic non-malignant pain. Abstracts of pain in the 5th Congress of the European Federation of IASP Chapters (EFIC), 13-16 September 2006, Istanbul, Turkey.
28. ® SMAT) in patients with chronic nonmalignant pain. Abstracts of pain in the 5th Congress of the European Federation of IASP Chapters (EFIC), 13-16 September 2006, Istanbul, Turkey.
29. Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 2005;49(7):902-8. (Pubitemid 41076330)
30. Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005;5(5):324-36. (Pubitemid 41486231)